Header Logo

Connection

Yehuda Handelsman to Humans

Back to Details
This is a "connection" page, showing publications Yehuda Handelsman has written about Humans.
Yehuda Handelsman
Connection Strength
4.671
Humans
  1. Lipid-lowering efficacy of obicetrapib: A comprehensive systematic review and meta-analysis. J Clin Lipidol. 2025 May-Jun; 19(3):412-421.
    View in: PubMed
    Score: 0.108
  2. Diabetes, cardiorenal, and metabolic multispecialty practice recommendations and early intensive management of cardio-renal-metabolic disease. Am J Manag Care. 2024 Dec; 30(10 Suppl):S189-S196.
    View in: PubMed
    Score: 0.107
  3. DCRM 2.0: Multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases. Metabolism. 2024 Oct; 159:155931.
    View in: PubMed
    Score: 0.104
  4. Cardiovascular Outcomes in Patients With Diabetes and Kidney Disease: JACC Review Topic of the Week. J Am Coll Cardiol. 2023 07 11; 82(2):161-170.
    View in: PubMed
    Score: 0.097
  5. Early intervention and intensive management of patients with diabetes, cardiorenal, and metabolic diseases. J Diabetes Complications. 2023 02; 37(2):108389.
    View in: PubMed
    Score: 0.094
  6. Impact of dronedarone on patients with atrial fibrillation and diabetes: A sub-analysis of the ATHENA and EURIDIS/ADONIS studies. J Diabetes Complications. 2022 07; 36(7):108227.
    View in: PubMed
    Score: 0.090
  7. DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases. J Diabetes Complications. 2022 02; 36(2):108101.
    View in: PubMed
    Score: 0.087
  8. Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Management of Dyslipidemia and Prevention of Cardiovascular Disease Algorithm - 2020 Executive Summary. Endocr Pract. 2020 Oct; 26(10):1196-1224.
    View in: PubMed
    Score: 0.080
  9. Paradigm shift in the management of DM & CVD-preventing the next CV event. J Diabetes. 2020 Sep; 12(9):630-632.
    View in: PubMed
    Score: 0.080
  10. Sodium-glucose cotransporter 2 inhibitors for macroalbuminuria: A new indication. J Diabetes. 2020 Jan; 12(1):8-9.
    View in: PubMed
    Score: 0.076
  11. Combining GLP-1 Receptor Agonists and Basal Insulin in Older Adults with Type 2 Diabetes: Focus on Lixisenatide and Insulin Glargine. Adv Ther. 2019 12; 36(12):3321-3339.
    View in: PubMed
    Score: 0.075
  12. Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes. Adv Ther. 2019 10; 36(10):2567-2586.
    View in: PubMed
    Score: 0.074
  13. Gerald Reaven: A man for our times. Diab Vasc Dis Res. 2019 03; 16(2):113-115.
    View in: PubMed
    Score: 0.072
  14. Cardiovascular events and death after myocardial infarction or ischemic stroke in an older Medicare population. Clin Cardiol. 2019 Mar; 42(3):391-399.
    View in: PubMed
    Score: 0.072
  15. Fournier's gangrene and sodium-glucose cotransporter 2 inhibitors: Is there a causal association? J Diabetes. 2019 05; 11(5):340-341.
    View in: PubMed
    Score: 0.072
  16. Sustained 52-week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes. Diabetes Obes Metab. 2019 04; 21(4):883-892.
    View in: PubMed
    Score: 0.071
  17. Notes from the world congress on insulin resistance, diabetes, and cardiovascular disease. J Diabetes. 2019 Apr; 11(4):258-260.
    View in: PubMed
    Score: 0.071
  18. Efficacy and safety of insulin glargine/lixisenatide (iGlarLixi) fixed-ratio combination in older adults with type 2 diabetes. J Diabetes Complications. 2019 03; 33(3):236-242.
    View in: PubMed
    Score: 0.071
  19. Glycemic Efficacy, Weight Effects, and Safety of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists. J Manag Care Spec Pharm. 2018 Sep; 24(9-a Suppl):S14-S29.
    View in: PubMed
    Score: 0.070
  20. World congress on insulin resistance, diabetes and cardiovascular disease. J Diabetes. 2018 Oct; 10(10):776-777.
    View in: PubMed
    Score: 0.069
  21. PCSK9 Inhibitors in Lipid Management of Patients With Diabetes Mellitus and High Cardiovascular Risk: A Review. J Am Heart Assoc. 2018 06 22; 7(13).
    View in: PubMed
    Score: 0.069
  22. Transition from hospital to outpatient diabetes care. J Diabetes. 2018 Jul; 10(7):538-540.
    View in: PubMed
    Score: 0.068
  23. How does CKD affect HbA1c? J Diabetes. 2018 Apr; 10(4):270.
    View in: PubMed
    Score: 0.066
  24. Concomitant Diabetes and Atrial?Fibrillation: No Sugarcoating the Bittersweet Reality. J Am Coll Cardiol. 2017 09 12; 70(11):1336-1338.
    View in: PubMed
    Score: 0.065
  25. A randomized, double-blind, non-inferiority trial evaluating the efficacy and safety of omarigliptin, a once-weekly DPP-4 inhibitor, or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy. Curr Med Res Opin. 2017 10; 33(10):1861-1868.
    View in: PubMed
    Score: 0.064
  26. Lipid-lowering efficacy and safety of alirocumab in patients with or without diabetes: A sub-analysis of ODYSSEY COMBO II. Diabetes Obes Metab. 2017 07; 19(7):989-996.
    View in: PubMed
    Score: 0.063
  27. Diabetes treatment over age 65: Is worse control really better? J Diabetes. 2017 May; 9(5):428-430.
    View in: PubMed
    Score: 0.063
  28. TRIGLYCERIDES, ATHEROSCLEROSIS, AND CARDIOVASCULAR OUTCOME STUDIES: FOCUS ON OMEGA-3 FATTY ACIDS. Endocr Pract. 2017 Jan; 23(1):100-112.
    View in: PubMed
    Score: 0.061
  29. Lorcaserin treatment allows for decreased number needed to treat for weight and glycemic parameters in week 12 responders with =5% weight loss. Postgrad Med. 2016 Nov; 128(8):740-746.
    View in: PubMed
    Score: 0.061
  30. Approaches to treatment 2: Comparison of American Association of Clinical Endocrinologists (AACE) and American Diabetes Association (ADA) type 2 diabetes treatment guidelines. J Diabetes. 2016 Jan; 8(1):4-6.
    View in: PubMed
    Score: 0.057
  31. SGLT-2 INHIBITION ADDED TO GLP-1 AGONIST THERAPY FOR TYPE 2 DIABETES: WHAT IS THE BENEFIT? Endocr Pract. 2015 Dec; 21(12):1442-4.
    View in: PubMed
    Score: 0.057
  32. POTENTIAL PLACE OF SGLT2 INHIBITORS IN TREATMENT PARADIGMS FOR TYPE 2 DIABETES MELLITUS. Endocr Pract. 2015 Sep; 21(9):1054-65.
    View in: PubMed
    Score: 0.056
  33. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY--CLINICAL PRACTICE GUIDELINES FOR DEVELOPING A DIABETES MELLITUS COMPREHENSIVE CARE PLAN--2015--EXECUTIVE SUMMARY. Endocr Pract. 2015 Apr; 21(4):413-37.
    View in: PubMed
    Score: 0.055
  34. Efficacy and safety of the once-weekly GLP-1 receptor agonist albiglutide versus sitagliptin in patients with type 2 diabetes and renal impairment: a randomized phase III study. Diabetes Care. 2014 Oct; 37(10):2723-30.
    View in: PubMed
    Score: 0.052
  35. Lessons from glargine trials: what is the goal fasting glucose with basal insulin? J Diabetes. 2014 Jul; 6(4):271-3.
    View in: PubMed
    Score: 0.051
  36. Reduced risk of hypoglycemia with insulin degludec versus insulin glargine in patients with type 2 diabetes requiring high doses of basal insulin: a meta-analysis of 5 randomized begin trials. Endocr Pract. 2014 Apr; 20(4):285-92.
    View in: PubMed
    Score: 0.051
  37. Diabetes and cancer--an AACE/ACE consensus statement. Endocr Pract. 2013 Jul-Aug; 19(4):675-93.
    View in: PubMed
    Score: 0.049
  38. Sugar-sweetened beverages: changing the tide. J Diabetes. 2013 Mar; 5(1):1-2.
    View in: PubMed
    Score: 0.047
  39. The clinical approach to the detection of lipodystrophy - an AACE consensus statement. Endocr Pract. 2013 Jan-Feb; 19(1):107-16.
    View in: PubMed
    Score: 0.047
  40. American Association of Clinical Endocrinologists' position statement on clinical nutrition and health promotion in endocrinology. Endocr Pract. 2012 Sep-Oct; 18(5):633-41.
    View in: PubMed
    Score: 0.046
  41. Did AIM-HIGH aim too low? J Diabetes. 2012 Mar; 4(1):1-2.
    View in: PubMed
    Score: 0.044
  42. An interview with the authors of Did AIM-HIGH aim too low. Interview by Jinghong Xu. J Diabetes. 2012 Mar; 4(1):3.
    View in: PubMed
    Score: 0.044
  43. Is combination therapy an effective way of reaching lipid goals in type 2 diabetes mellitus? Expert Rev Clin Pharmacol. 2012 Jan; 5(1):43-54.
    View in: PubMed
    Score: 0.044
  44. Overcoming obstacles in risk factor management in type 2 diabetes mellitus. J Clin Hypertens (Greenwich). 2011 Aug; 13(8):613-20.
    View in: PubMed
    Score: 0.042
  45. Diabetes in youth: a dilemma of pathogenesis. J Diabetes. 2011 Jun; 3(2):91-2.
    View in: PubMed
    Score: 0.042
  46. Diabetes and hypertension: a comprehensive report on management and the prevention of cardiovascular and renal complications. J Clin Hypertens (Greenwich). 2011 Apr; 13(4):221-3.
    View in: PubMed
    Score: 0.042
  47. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive care plan. Endocr Pract. 2011 Mar-Apr; 17 Suppl 2:1-53.
    View in: PubMed
    Score: 0.041
  48. American Association of Clinical Endocrinologists Medical Guidelines for clinical practice for developing a diabetes mellitus comprehensive care plan: executive summary. Endocr Pract. 2011 Mar-Apr; 17(2):287-302.
    View in: PubMed
    Score: 0.041
  49. The Avandia debate: an unhappy conclusion. J Diabetes. 2010 Dec; 2(4):221-2.
    View in: PubMed
    Score: 0.041
  50. The role of bile acid sequestrants in the management of type 2 diabetes mellitus: summary and future directions. Metab Syndr Relat Disord. 2010 Dec; 8 Suppl 1:S23-4.
    View in: PubMed
    Score: 0.041
  51. Colesevelam hydrochloride to treat hypercholesterolemia and improve glycemia in prediabetes: a randomized, prospective study. Endocr Pract. 2010 Jul-Aug; 16(4):617-28.
    View in: PubMed
    Score: 0.039
  52. Insulin treatment of Type 2 diabetes: a clinical perspective. J Diabetes. 2010 Jun; 2(2):65-6.
    View in: PubMed
    Score: 0.039
  53. Colesevelam HCl improves fasting plasma glucose and lipid levels in patients with prediabetes. Postgrad Med. 2009 Nov; 121(6):62-9.
    View in: PubMed
    Score: 0.038
  54. Cancer mortality and insulin glargine. J Diabetes. 2009 Sep; 1(3):131-3.
    View in: PubMed
    Score: 0.037
  55. The use of the bile acid sequestrant colesevelam HCl in patients with type 2 diabetes mellitus: for glucose and lipid control. Introduction. Postgrad Med. 2009 May; 121(3 Suppl 1):5-6.
    View in: PubMed
    Score: 0.036
  56. The role of colesevelam HCl in type 2 diabetes mellitus therapy. Postgrad Med. 2009 May; 121(3 Suppl 1):19-24.
    View in: PubMed
    Score: 0.036
  57. Metabolic syndrome pathophysiology and clinical presentation. Toxicol Pathol. 2009 Jan; 37(1):18-20.
    View in: PubMed
    Score: 0.035
  58. Pharmacologic treatment options for prediabetes. Nat Clin Pract Endocrinol Metab. 2008 Jul; 4(7):380-1.
    View in: PubMed
    Score: 0.034
  59. Treating diabetes with incretin hormones - clinical experience. Pediatr Endocrinol Rev. 2008 Jun; 5(4):897-903.
    View in: PubMed
    Score: 0.034
  60. Cardiovascular Outcomes and Efficacy of the PCSK9 Inhibitor Evolocumab in Individuals With Type 1 Diabetes: Insights From the FOURIER Trial. Diabetes Care. 2025 Sep 01; 48(9):1512-1516.
    View in: PubMed
    Score: 0.028
  61. Use of finerenone in patients with chronic kidney disease at high risk of heart failure. Metabolism. 2025 Aug; 169:156297.
    View in: PubMed
    Score: 0.028
  62. Intense simplified strategy for newly diagnosed type 2 diabetes in patients with severe hyperglycaemia: multicentre, open label, randomised trial. BMJ. 2024 10 15; 387:e080122.
    View in: PubMed
    Score: 0.027
  63. Study protocol for a prospective, multicentre study of hypercortisolism in patients with difficult-to-control type 2 diabetes (CATALYST): prevalence and treatment with mifepristone. BMJ Open. 2024 07 16; 14(7):e081121.
    View in: PubMed
    Score: 0.026
  64. Immunogenicity, Efficacy, and Safety of Biosimilar Insulin Glargine (Gan & Lee Glargine) Compared With Originator Insulin Glargine (Lantus) in Patients With Type 1 Diabetes After 26?Weeks Treatment. Endocr Pract. 2024 Sep; 30(9):810-816.
    View in: PubMed
    Score: 0.026
  65. Cardio-renal-metabolic disease in primary care setting. Diabetes Metab Res Rev. 2024 Mar; 40(3):e3755.
    View in: PubMed
    Score: 0.025
  66. Treatment of the insulin resistance syndrome. Endocr Pract. 2003 Sep-Oct; 9 Suppl 2:99-104.
    View in: PubMed
    Score: 0.025
  67. DCRM Multispecialty Recommendations in Patients With Heart Failure. J Card Fail. 2022 11; 28(11):1642-1645.
    View in: PubMed
    Score: 0.023
  68. Icosapent ethyl for reduction of persistent cardiovascular risk: a critical review of major medical society guidelines and statements. Expert Rev Cardiovasc Ther. 2022 Aug; 20(8):609-625.
    View in: PubMed
    Score: 0.023
  69. American Association of Clinical Endocrinology Clinical Practice Guideline: The Use of Advanced Technology in the Management of Persons With Diabetes Mellitus. Endocr Pract. 2021 06; 27(6):505-537.
    View in: PubMed
    Score: 0.021
  70. Cardiovascular Outcomes and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: Current Data and Future Prospects. Vasc Health Risk Manag. 2020; 16:403-418.
    View in: PubMed
    Score: 0.020
  71. Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure: The Need for Further Evidence Generation and Practice Guidelines Optimization. Circulation. 2020 09 22; 142(12):1205-1218.
    View in: PubMed
    Score: 0.020
  72. Use of sodium-glucose co-transporter-2 inhibitors in patients with and without type 2 diabetes: implications for incident and prevalent heart failure. Eur J Heart Fail. 2020 04; 22(4):604-617.
    View in: PubMed
    Score: 0.019
  73. CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2020 EXECUTIVE SUMMARY. Endocr Pract. 2020 01; 26(1):107-139.
    View in: PubMed
    Score: 0.019
  74. Efficacy and safety of evolocumab in individuals with type 2 diabetes mellitus: primary results of the randomised controlled BANTING study. Diabetologia. 2019 06; 62(6):948-958.
    View in: PubMed
    Score: 0.018
  75. CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2019 EXECUTIVE SUMMARY. Endocr Pract. 2019 01; 25(1):69-100.
    View in: PubMed
    Score: 0.018
  76. EFFICACY AND SAFETY OF IDEGLIRA IN OLDER PATIENTS WITH TYPE 2 DIABETES. Endocr Pract. 2019 Feb; 25(2):144-155.
    View in: PubMed
    Score: 0.018
  77. DYSGLYCEMIA-BASED CHRONIC DISEASE: AN AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS POSITION STATEMENT. Endocr Pract. 2018 Nov; 24(11):995-1011.
    View in: PubMed
    Score: 0.018
  78. Burden of Illness in Type 2 Diabetes Mellitus. J Manag Care Spec Pharm. 2018 Sep; 24(9-a Suppl):S5-S13.
    View in: PubMed
    Score: 0.017
  79. Cardiovascular Outcomes with Once-Weekly GLP-1 RAs: Clinical and Economic Implications. J Manag Care Spec Pharm. 2018 Sep; 24(9-a Suppl):S42-S52.
    View in: PubMed
    Score: 0.017
  80. Health-Related Quality of Life Assessments with Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus. J Manag Care Spec Pharm. 2018 Sep; 24(9-a Suppl):S30-S41.
    View in: PubMed
    Score: 0.017
  81. Propensity-score-matched comparative analyses of simultaneously administered fixed-ratio insulin glargine 100?U and lixisenatide (iGlarLixi) vs sequential administration of insulin glargine and lixisenatide in uncontrolled type 2 diabetes. Diabetes Obes Metab. 2018 12; 20(12):2821-2829.
    View in: PubMed
    Score: 0.017
  82. American College of Physicians diabetes guidelines attempt to turn back the clock, conflating good HbA1c with hypoglycemia. J Diabetes. 2018 Aug; 10(8):618-620.
    View in: PubMed
    Score: 0.017
  83. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY 2018 POSITION STATEMENT ON INTEGRATION OF INSULIN PUMPS AND CONTINUOUS GLUCOSE MONITORING IN PATIENTS WITH DIABETES MELLITUS. Endocr Pract. 2018 Mar; 24(3):302-308.
    View in: PubMed
    Score: 0.017
  84. CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2018 EXECUTIVE SUMMARY. Endocr Pract. 2018 01; 24(1):91-120.
    View in: PubMed
    Score: 0.017
  85. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON TESTING FOR AUTONOMIC AND SOMATIC NERVE DYSFUNCTION. Endocr Pract. 2017 Dec; 23(12):1472-1478.
    View in: PubMed
    Score: 0.017
  86. AACE/ACE POSITION STATEMENT ON THE USE OF FOLLOW-ON BIOLOGICS AND BIOSIMILARS FOR ENDOCRINE DISEASES. Endocr Pract. 2017 Nov; 23(11):1345-1349.
    View in: PubMed
    Score: 0.016
  87. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes Endocrinol. 2017 12; 5(12):941-950.
    View in: PubMed
    Score: 0.016
  88. Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes: The SWITCH 2 Randomized Clinical Trial. JAMA. 2017 Jul 04; 318(1):45-56.
    View in: PubMed
    Score: 0.016
  89. JCL roundtable: Future of the lipid laboratory: Using the laboratory to manage the patient (part 2). J Clin Lipidol. 2017 Jul - Aug; 11(4):846-854.
    View in: PubMed
    Score: 0.016
  90. JCL roundtable: Future of the lipid laboratory: Choosing valuable measures among the lipoproteins (part 1). J Clin Lipidol. 2017 May - Jun; 11(3):587-595.
    View in: PubMed
    Score: 0.016
  91. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE. Endocr Pract. 2017 Apr; 23(Suppl 2):1-87.
    View in: PubMed
    Score: 0.016
  92. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE - EXECUTIVE SUMMARYComplete Appendix to Guidelines available at http://journals.aace.com. Endocr Pract. 2017 Apr 02; 23(4):479-497.
    View in: PubMed
    Score: 0.016
  93. CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2017 EXECUTIVE SUMMARY. Endocr Pract. 2017 02; 23(2):207-238.
    View in: PubMed
    Score: 0.016
  94. Differentiation of Diabetes by Pathophysiology, Natural History, and Prognosis. Diabetes. 2017 02; 66(2):241-255.
    View in: PubMed
    Score: 0.015
  95. CONTINUOUS GLUCOSE MONITORING: A CONSENSUS CONFERENCE OF THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY. Endocr Pract. 2016 Aug; 22(8):1008-21.
    View in: PubMed
    Score: 0.015
  96. TRANSCULTURALIZATION RECOMMENDATIONS FOR DEVELOPING LATIN AMERICAN CLINICAL PRACTICE ALGORITHMS IN ENDOCRINOLOGY--PROCEEDINGS OF THE 2015 PAN-AMERICAN WORKSHOP BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY. Endocr Pract. 2016 Apr; 22(4):476-501.
    View in: PubMed
    Score: 0.015
  97. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY 2016 OUTPATIENT GLUCOSE MONITORING CONSENSUS STATEMENT. Endocr Pract. 2016 Feb; 22(2):231-61.
    View in: PubMed
    Score: 0.015
  98. CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM--2016 EXECUTIVE SUMMARY. Endocr Pract. 2016 Jan; 22(1):84-113.
    View in: PubMed
    Score: 0.014
  99. CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM--2015 EXECUTIVE SUMMARY. Endocr Pract. 2015 Dec; 21(12):1403-14.
    View in: PubMed
    Score: 0.014
  100. The CardioMetabolic Health Alliance: Working Toward a New Care Model for the Metabolic Syndrome. J Am Coll Cardiol. 2015 Sep 01; 66(9):1050-67.
    View in: PubMed
    Score: 0.014
  101. PATIENTS ACHIEVING GOOD GLYCEMIC CONTROL (HBA1c <7%) EXPERIENCE A LOWER RATE OF HYPOGLYCEMIA WITH INSULIN DEGLUDEC THAN WITH INSULIN GLARGINE: A META-ANALYSIS OF PHASE 3A TRIALS. Endocr Pract. 2015 Aug; 21(8):917-26.
    View in: PubMed
    Score: 0.014
  102. Proceedings from the American Association of Clinical Endocrinologists and American College of Endocrinology consensus conference on glucose monitoring. Endocr Pract. 2015 May; 21(5):522-33.
    View in: PubMed
    Score: 0.014
  103. AACE/ACE comprehensive diabetes management algorithm 2015. Endocr Pract. 2015 Apr; 21(4):438-47.
    View in: PubMed
    Score: 0.014
  104. Consensus Statement by the American Association of Clinical Endocrinologists/American College of Endocrinology insulin pump management task force. Endocr Pract. 2014 May; 20(5):463-89.
    View in: PubMed
    Score: 0.013
  105. Practical perspectives on the management of overweight and obesity. Am J Manag Care. 2014 Mar; 20(3 Suppl):S64-75.
    View in: PubMed
    Score: 0.013
  106. Health status and hypoglycaemia with insulin degludec versus insulin glargine: a 2-year trial in insulin-na?ve patients with type 2 diabetes. Diabetes Obes Metab. 2014 Sep; 16(9):869-72.
    View in: PubMed
    Score: 0.013
  107. A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON). Diabetes Obes Metab. 2014 Jul; 16(7):636-44.
    View in: PubMed
    Score: 0.013
  108. Comparison of insulin degludec with insulin glargine in insulin-naive subjects with Type?2 diabetes: a 2-year randomized, treat-to-target trial. Diabet Med. 2013 Nov; 30(11):1298-304.
    View in: PubMed
    Score: 0.012
  109. The Journal of diabetes: continuing the dialogue. J Diabetes. 2013 Jun; 5(2):95-6.
    View in: PubMed
    Score: 0.012
  110. American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement--executive summary. Endocr Pract. 2013 May-Jun; 19(3):536-57.
    View in: PubMed
    Score: 0.012
  111. The role of bromocriptine-QR in the management of type 2 diabetes expert panel recommendations. Endocr Pract. 2013 Jan-Feb; 19(1):100-6.
    View in: PubMed
    Score: 0.012
  112. Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long). Diabetes Care. 2012 Dec; 35(12):2464-71.
    View in: PubMed
    Score: 0.012
  113. American Association of Clinical Endocrinologists' position statement on obesity and obesity medicine. Endocr Pract. 2012 Sep-Oct; 18(5):642-8.
    View in: PubMed
    Score: 0.011
  114. Initial combination therapy with metformin plus colesevelam in drug-na?ve Hispanic patients with early type 2 diabetes. Postgrad Med. 2012 Jul; 124(4):7-13.
    View in: PubMed
    Score: 0.011
  115. Clinical effects of colesevelam in Hispanic subjects with primary hyperlipidemia and prediabetes. Postgrad Med. 2012 Jul; 124(4):14-20.
    View in: PubMed
    Score: 0.011
  116. American Association of Clinical Endocrinologists' Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis: executive summary. Endocr Pract. 2012 Mar-Apr; 18(2):269-93.
    View in: PubMed
    Score: 0.011
  117. American Association of Clinical Endocrinologists' Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis. Endocr Pract. 2012 Mar-Apr; 18 Suppl 1:1-78.
    View in: PubMed
    Score: 0.011
  118. Effectiveness of primary care-relevant treatments for obesity in adults. Ann Intern Med. 2012 Feb 07; 156(3):248-9; author reply 249.
    View in: PubMed
    Score: 0.011
  119. Comprehensive diabetes cardiovascular treatment = sugar + blood pressure + lipids. J Diabetes. 2011 Dec; 3(4):257-60.
    View in: PubMed
    Score: 0.011
  120. Iron-deficiency anemia, non-iron-deficiency anemia and HbA1c among adults in the US. J Diabetes. 2011 Mar; 3(1):67-73.
    View in: PubMed
    Score: 0.010
  121. Good news! J Diabetes. 2010 Sep; 2(3):127.
    View in: PubMed
    Score: 0.010
  122. Gut hormones and the brain. J Diabetes. 2010 Sep; 2(3):138-45.
    View in: PubMed
    Score: 0.010
  123. Statement by the American Association of Clinical Endocrinologists Consensus Panel on insulin pump management. Endocr Pract. 2010 Sep-Oct; 16(5):746-62.
    View in: PubMed
    Score: 0.010
  124. Initial combination therapy with metformin and colesevelam for achievement of glycemic and lipid goals in early type 2 diabetes. Endocr Pract. 2010 Jul-Aug; 16(4):629-40.
    View in: PubMed
    Score: 0.010
  125. Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence. Diabetes Obes Metab. 2010 May; 12(5):384-92.
    View in: PubMed
    Score: 0.010
  126. Bile acid sequestrants for lipid and glucose control. Curr Diab Rep. 2010 Feb; 10(1):70-7.
    View in: PubMed
    Score: 0.010
  127. Effects of colesevelam, rosiglitazone, or sitagliptin on glycemic control and lipid profile in patients with type 2 diabetes mellitus inadequately controlled by metformin monotherapy. Endocr Pract. 2010 Jan-Feb; 16(1):53-63.
    View in: PubMed
    Score: 0.010
  128. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009 Sep-Oct; 15(6):540-59.
    View in: PubMed
    Score: 0.009
  129. Diagnosis and management of prediabetes in the continuum of hyperglycemia: when do the risks of diabetes begin? A consensus statement from the American College of Endocrinology and the American Association of Clinical Endocrinologists. Endocr Pract. 2008 Oct; 14(7):933-46.
    View in: PubMed
    Score: 0.009
  130. Road maps to achieve glycemic control in type 2 diabetes mellitus: ACE/AACE Diabetes Road Map Task Force. Endocr Pract. 2007 May-Jun; 13(3):260-8.
    View in: PubMed
    Score: 0.008
  131. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract. 2007 May-Jun; 13 Suppl 1:1-68.
    View in: PubMed
    Score: 0.008
  132. Hypoglycemia in the intensive care unit. Curr Opin Clin Nutr Metab Care. 2007 Mar; 10(2):193-6.
    View in: PubMed
    Score: 0.008
  133. ACE/AACE consensus conference on the implementation of outpatient management of diabetes mellitus: consensus conference recommendations. Endocr Pract. 2006 Jan-Feb; 12 Suppl 1:6-12.
    View in: PubMed
    Score: 0.007
  134. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract. 2003 May-Jun; 9(3):237-52.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.